Cellectar Biosciences, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Cellectar is a clinical-stage biopharmaceutical company developing cancer treatments using its phospholipid drug conjugate (PDC) platform. The filing reports no revenue; it is focused on research and development.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 or comparison |
|---|---|---|
| Research and development expense | $4.63 million | $2.62 million; up 77% |
| General and administrative expense | $1.73 million | $1.34 million; up 29% |
| Total operating expenses / loss from operations | $6.36 million | $3.96 million |
| Net loss | $6.36 million | $3.96 million |
| Basic and diluted loss per share | $0.13 | $0.42 |
| Cash used in operating activities | $4.75 million | $3.51 million |
Cash and cash equivalents were $53.63 million at March 31, 2021, down from $57.17 million at year-end 2020. Current assets were $54.40 million and current liabilities $5.02 million. Total liabilities were $5.29 million, including lease liabilities; the company reported no outstanding PPP loan, which had been forgiven in December 2020. There is no meaningful operating margin to compare because the filing reports no revenue.
Management said cash was sufficient for basic budgeted operations for at least 12 months from the filing date, but execution of the operating plan beyond that depends on additional financing, a strategic transaction or other funding. The company has an accumulated deficit of $133.13 million and expects continued operating losses.
Material changes and financing
- R&D expense rose by $2.02 million, mainly from approximately $2.10 million higher clinical-study costs; manufacturing and preclinical costs declined.
- G&A expense increased by $384,000, primarily due to professional fees and insurance.
- During Q1, holders converted 574.0736 Series D preferred shares into 5,740,736 common shares, and warrants were exercised for 1,005,320 common shares, generating $1.21 million. Common shares outstanding rose to 52.73 million from 45.44 million at December 31, 2020.
- Stockholders approved increasing authorized common shares from 80 million to 160 million. At March 31, 16.45 million warrants were outstanding, in addition to options and convertible preferred shares, creating potential dilution.
Business outlook, developments and risks
- Lead candidate CLR 131 was being studied in pivotal Phase 2 CLOVER-WaM for relapsed/refractory Waldenstrom’s macroglobulinemia, a Phase 2B multiple-myeloma study, and a Phase 1 pediatric-cancer study. The filing says the FDA agreed on key CLOVER-WaM design elements, including a 50-patient study and an initial safety/futility assessment.
- Management reported earlier study results, including responses in small patient cohorts; these are clinical observations, not evidence of regulatory approval or commercial success. The Phase 1 multiple-myeloma study’s final report was expected in the first half of 2021.
- Other programs include preclinical CLR 1900 and partnered PDC programs. The company also described three ongoing collaborations.
- COVID-19 had not yet caused significant reported business impacts, but could affect clinical-trial recruitment, CLR 131 supply and access to financing. Cellectar identified its sole CLR 131 supplier as a potential disruption risk.
- Other key uncertainties include clinical outcomes and timing, the need for additional capital, and the company’s ability to advance candidates. Legal matters in the ordinary course were not expected to materially affect the financial statements; no legal proceedings were listed. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Investor verification points
- Check subsequent filings for actual cash runway, financing activity and any change to the stated 12-month funding outlook.
- Verify CLOVER-WaM enrollment, safety/futility review and study progress, along with final reports and updated results for other CLR 131 trials.
- Review the impact of outstanding warrants, preferred conversions, options and the enlarged authorized share count on potential dilution.
- Monitor clinical-trial recruitment, manufacturing continuity and any COVID-19-related effects on development timelines.